StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.00 (-0.65%)

Close on Nov 17, 2026Market cap $257.81KP/E –Yield –

Virax Biolabs r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $3.74M, up 84.0% from the year before. The highest annual figure on record is $3.74M in fiscal 2026.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$3.74M+84.0%
FY2025Mar 31, 2025$2.03M+25.8%
FY2024Mar 31, 2024$1.61M-25.9%
FY2023Mar 31, 2023$2.18M+402.4%
FY2022Mar 31, 2022$433.74K+260.8%
FY2021Mar 31, 2021$120.22K–

More Virax Biolabs figures

See a number that looks wrong?